Gt biopharma announces update on the commencement of the gtb-3550 trike™ monotherapy phase 2 clinical trial and solid tumor trike™ product candidates

Beverly hills, calif., may 12, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform, is pleased to provide an update concerning the commencement of the gtb-3550 trike™ monotherapy phase 2 clinical trial, and certain of its solid tumor targeting trike™ product candidates.
GTBP Ratings Summary
GTBP Quant Ranking